ArticleThe Journal of biological chemistry2011
Immunochemical analysis of the electronegative LDL subfraction shows that abnormal N-terminal apolipoprotein B conformation is involved in increased binding to proteoglycans.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome.Lipids in health and disease · 2020Trial
- The lysophosphatidylcholine-HIF-1α axis enhances apolipoprotein E sialylation and promotes electronegative LDL accumulation.iScience · 2026Article
- LDL binding to cell receptors and extracellular matrix is proatherogenic in obesity but improves after bariatric surgery.Journal of lipid research · 2023Article
- Can Electronegative LDL Act as a Multienzymatic Complex?International journal of molecular sciences · 2023Review
- Presence of Ceramidase Activity in Electronegative LDL.International journal of molecular sciences · 2022Article
- Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies.Journal of clinical medicine · 2021Review
- Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases.Biomedicines · 2020Review
- Electronegative Low-Density Lipoprotein L5 Impairs Viability and NGF-Induced Neuronal Differentiation of PC12 Cells via LOX-1.International journal of molecular sciences · 2017Article
- Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation.Biochimica et biophysica acta · 2016Article
- LDL electronegativity index: a potential novel index for predicting cardiovascular disease.Vascular health and risk management · 2015Review
- The underlying chemistry of electronegative LDL's atherogenicity.Current atherosclerosis reports · 2014Review
- The Induction of Cytokine Release in Monocytes by Electronegative Low-Density Lipoprotein (LDL) Is Related to Its Higher Ceramide Content than Native LDL.International journal of molecular sciences · 2013Article
- Electronegative LDL: a circulating modified LDL with a role in inflammation.Mediators of inflammation · 2013Review
- Kinetic analysis of thermal stability of human low density lipoproteins: a model for LDL fusion in atherogenesis.Journal of lipid research · 2012Article
- Article
- Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH.Journal of lipid research · 2012Article
- Effects of electronegative VLDL on endothelium damage in metabolic syndrome.Diabetes care · 2012Article
- Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein.Pure and applied chemistry. Chimie pure et appliquee · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electronegative LDL (LDL(-)) is a minor subfraction of modified LDL present in plasma. Among its atherogenic characteristics, low affinity to the LDL receptor and high binding to arterial proteoglycans (PGs) could be related to abnormalities in the conformation of its main protein, apolipoprotein B-100 (apoB-100). In the current study, we have performed an immunochemical analysis using monoclonal antibody (mAb) probes to analyze the conformation of apoB-100 in LDL(-). The study, performed with 28 anti-apoB-100 mAbs, showed that major differences of apoB-100 immunoreactivity between native LDL and LDL(-) concentrate in both terminal extremes. The mAbs Bsol 10, Bsol 14 (which recognize the amino-terminal region), Bsol 2, and Bsol 7 (carboxyl-terminal region) showed increased immunoreactivity in LDL(-), suggesting that both terminal extremes are more accessible in LDL(-) than in native LDL. The analysis of in vitro-modified LDLs, including LDL lipolyzed with sphingomyelinase (SMase-LDL) or phospholipase A(2) (PLA(2)-LDL) and oxidized LDL (oxLDL), suggested that increased amino-terminal immunoreactivity was related to altered conformation due to aggregation. This was confirmed when the aggregated subfractions of LDL(-) (agLDL(-)) and oxLDL (ag-oxLDL) were isolated and analyzed. Thus, Bsol 10 and Bsol 14 immunoreactivity was high in SMase-LDL, ag-oxLDL, and agLDL(-). The altered amino-terminal apoB-100 conformation was involved in the increased PG binding affinity of agLDL(-) because Bsol 10 and Bsol 14 blocked its high PG-binding. These observations suggest that an abnormal conformation of the amino-terminal region of apoB-100 is responsible for the increased PG binding affinity of agLDL(-).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.